The development of an innovative interactive online platform for clinical trials

拟议的解决方案将是开发一个智能的基于云的招聘和沟通平台，用于连接医疗保健专业人员、科学家、研究护士、试验协调员和患者，以更好地获取和传递临床试验知识www.youtreatmentchoices.com。该平台允许患者观看和收听研究医生解释单个试验的目的和要求以及直接参与研究的设施的视频团队该解决方案的创新之处在于开发了一种自动筛选工具，用于使用数据挖掘选择患者。NHS中的各种医学治疗对患者不再有效。NHS创新的平均时间表为17年，改善新治疗试验的可及性和可用性对于NHS增加试验成功和创新至关重要。目前的试验失败是由于招募患者的挑战，导致10项试验中有4项未完成。到2014年，患者招募目标为每季度125，000人，英国市场代表着一个强大的机会。在英国，进行临床试验的成本占制药公司药物开发预算的30%，约占临床试验总成本的40%，而时间是导致70%临床试验失败的主要原因。在使制药公司大幅减少临床试验成本和时间的同时，该平台将鼓励患者通过更好的教育手段，了解自己的病情和治疗情况，在管理自己的疾病方面发挥积极作用。有了这个项目，不仅有助于在时间和成本上达到患者招募目标，而且还可以提高英国新治疗和医学研究的机会。该项目将为制药行业带来直接价值，使英国整体医疗保健研究和经济受益。

The proposed solution will be the development of an intelligent cloud-based recruitment andcommunication platform for connecting healthcare professionals, scientists, research nurses,trial coordinators and patients for better knowledge access and transfer on clinical trials.Called “www.youtreatmentchoices.com”, the platform allows patients to watch and listen tovideos of research doctors explaining the purpose and requirements of individual trials and thefacility to engage directly with research teams. The innovativeness of the solution lies withindeveloping an automated screening tool for selecting patients using data mining. Variouscases of medical treatments in the NHS no longer prove effective for patients. With averagetimelines for innovations in the NHS of 17 years, the improvement of access and availabilityto new treatment trials is vital for increased trials successes and innovations in the NHS.Current trial failures are due to the challenge of recruiting patients resulting in 4 trials out of10 non-completed. With a patient recruitment target of 125,000 per quarter year by 2014, themarket in the UK represents a strong opportunity. The cost of running clinical trials in the UKamounts up to 30% of pharmaceutical companies’ drug development budget, consumingapproximately 40% of total clinical trial costs with time being a prime cause for 70% ofclinical trial failures.While enabling pharmaceutical companies to significantly reduce thecost and time of clinical trials, the platform will encourage patients to take an active role inmanaging their own disease through better education means about their conditions andtreatment availability. With this the project will not only help to meet patient recruitmenttargets on time and costs but improve the opportunities of new treatments and medicalresearch in the UK. The project will deliver direct value to the pharmaceutical sector,benefiting the overall UK healthcare research and economy.